Spain's Grifols buys Talecris for $4 billion
MADRID |
MADRID (Reuters) - Spanish healthcare company Grifols (GRLS.MC) has acquired Talecris Biotherapuetics TLCR.O, which produces plasma-based protein therapies, for $4 billion including debt.
Grifols estimates about $230 million annual synergies from the deal, which has been unanimously approved by both companies' boards and recommended to their shareholders, the Spanish company said in a statement on Monday.
On Sunday, sources had told Reuters the deal was likely to be in cash and stock.
(Reporting by Tracy Rucinski; Editing by Paul Day)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints


Follow Reuters